Skip to main content
. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y

Fig. 4.

Fig. 4

Immune cell subsets of a potentially biologic relevance following different doses of avelumab. Graphs display frequency as a percentage of PBMC for patients treated with 1 or 3 mg/kg (left panels, triangle), 10 mg/kg (middle panels, circle), and 20 mg/kg (right panels, square) of avelumab